What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
Lu et al.1 previously demonstrated that antagonist antibodies against the GIP receptor promote weight loss combined with GLP-1. They now elegantly developed a conjugate of GIPR antibodies and GLP-1 and show effective weight loss in obese non-human primates.
Main Author: | Jens Juul Holst |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-05-01
|
Series: | Cell Reports Medicine |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666379121001129 |
Similar Items
-
Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
by: Sara Baldassano, et al.
Published: (2019-08-01) -
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
by: Francis S. Willard, et al.
Published: (2020-09-01) -
A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
by: Noura Al-Zamel, et al.
Published: (2019-07-01) -
Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists
by: Aaron Novikoff, et al.
Published: (2021-07-01) -
Emerging role of GLP-1 receptor agonists in the treatment of obesity
by: Neff LM
Published: (2010-07-01)